down arrow

Gyre Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4037831033
USD
7.13
-0.22 (-2.99%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.927.35

52 Week

6.1114.42
Valuation
Technical
Day's Volume

CASH

462.05 k

Shareholding (Mar 2025)

FII

0.24%

Held by 17 FIIs

DII

97.59%

Held by 2 DIIs

Promoter

0.01%

What does Gyre Therapeutics, Inc. do?

22-Jun-2025

Gyre Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently showing no dividend yield and negative financial metrics. No additional company details are available.

Overview: <BR>Gyre Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Market cap: Micro Cap<BR><BR>Key Metrics: <BR>Industry: Pharmaceuticals & Biotechnology <BR>Dividend Yield: 0.00% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: -999,999.00% <BR>Price to Book: 0.00 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Gyre Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of May 9, 2025, Gyre Therapeutics, Inc. is considered overvalued with a P/E ratio of 105.51 and an EV to EBITDA ratio of 57.93, significantly higher than industry averages, and has underperformed the S&P 500 with a year-to-date return of -36.45%.

As of 9 May 2025, the valuation grade for Gyre Therapeutics, Inc. has moved from fair to expensive, indicating that the company is overvalued. The P/E ratio stands at 105.51, significantly higher than the industry average, while the EV to EBITDA ratio is 57.93, further suggesting a premium valuation. The lack of a PEG ratio indicates that growth expectations may not justify the current price levels.<BR><BR>In comparison to peers, Gyre Therapeutics is notably more expensive, with its P/E ratio far exceeding typical valuations in the pharmaceuticals and biotechnology sector. For instance, while Gyre's P/E is 105.51, other companies in the industry may have much lower ratios, reflecting a more reasonable valuation. Additionally, the company's stock has underperformed against the S&P 500, with a year-to-date return of -36.45% compared to the S&P 500's 12.22%, reinforcing the notion that the stock may be overvalued given its performance trajectory.

Read More

Is Gyre Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Gyre Therapeutics, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly indicators suggest mild bullishness, despite significant underperformance against the S&P 500, with year-to-date and one-year returns of -36.45% and -44.56%, respectively.

As of 12 August 2025, the technical trend for Gyre Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD, KST, and Dow Theory show mildly bullish signals. However, Bollinger Bands remain bearish across both weekly and monthly time frames. The stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -36.45% versus the S&P 500's 12.22%, and a one-year return of -44.56% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Positive results in Jun 25

  • RAW MATERIAL COST(Y) Fallen by 1.3% (YoY)
2

With ROE of 0.00%, it has a does not qualify valuation with a 0.00 Price to Book Value

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 717 Million (Micro Cap)

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.58

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

7.79

Revenue and Profits:
Net Sales:
27 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.66%
0%
-1.66%
6 Months
-14.41%
0%
-14.41%
1 Year
-33.11%
0%
-33.11%
2 Years
-72.46%
0%
-72.46%
3 Years
-3.19%
0%
-3.19%
4 Years
-52.94%
0%
-52.94%
5 Years
-92.79%
0%
-92.79%

Gyre Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
44.24%
EBIT Growth (5y)
17.08%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.31%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (2.16%)

Foreign Institutions

Held by 17 Foreign Institutions (0.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 6.35% vs -13.99% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -64.44% vs 18.42% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26.80",
          "val2": "25.20",
          "chgp": "6.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.80",
          "val2": "3.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "2.90",
          "chgp": "-93.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.60",
          "val2": "4.50",
          "chgp": "-64.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "81.10%",
          "val2": "129.30%",
          "chgp": "-4.82%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.78% vs 10.95% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 120.94% vs -2,088.37% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.80",
          "val2": "113.50",
          "chgp": "-6.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "17.80",
          "val2": "20.30",
          "chgp": "-12.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "7.20",
          "val2": "-95.10",
          "chgp": "107.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.90",
          "val2": "-85.50",
          "chgp": "120.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.50%",
          "val2": "169.40%",
          "chgp": "-1.59%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
26.80
25.20
6.35%
Operating Profit (PBDIT) excl Other Income
2.80
3.50
-20.00%
Interest
0.00
0.00
Exceptional Items
0.20
2.90
-93.10%
Consolidate Net Profit
1.60
4.50
-64.44%
Operating Profit Margin (Excl OI)
81.10%
129.30%
-4.82%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 6.35% vs -13.99% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -64.44% vs 18.42% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
105.80
113.50
-6.78%
Operating Profit (PBDIT) excl Other Income
17.80
20.30
-12.32%
Interest
0.00
0.00
Exceptional Items
7.20
-95.10
107.57%
Consolidate Net Profit
17.90
-85.50
120.94%
Operating Profit Margin (Excl OI)
153.50%
169.40%
-1.59%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -6.78% vs 10.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 120.94% vs -2,088.37% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Gyre Therapeutics, Inc. stock-summary
stock-summary
Gyre Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."